Careers  |  Sign In  |  Register  |   Twitter

Antibody and Statin Therapy to Treat Hypercholesterolemia

Serum proprotein convertase subtilisin/kexin 9 (PCSK9) is a monoclonal antibody that increases recycling of LDL receptors and is hypothesized to reduce LDL in circulation. According to clinical trial results in The New England Journal of Medicine, treatment with atorvastatin and PCSK9 showed effective reduction of LDL levels over at least a 7 week regimen period. Results showed that the dual treatment resulted in a mean reduction of  73.2±3.5 mg per deciliter of LDL cholesterol in circulation as opposed to 17.3±3.5 reduction with just atorvastatin plus placebo.

Read it in NEJM.